The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)
For additional resources, visit Real Peptides
Retatrutide hits GLP-1, GIP, and glucagon
Heavy smokers and drinkers can also have low levels of B12
When I met Dave [Asprey] in 2016, I saw what this space could be
It can interfere with daily activities and impair willingness to go out with friends, speaking in public, going to the pool, etc